Observational studyBMC cancer2025
Incidence and risk factors for recurrent venous thromboembolism, recurrent stroke and bleeding in Chinese patients with acute ischemic stroke and cancer : a real-world study.
Observational study in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPatients with acute ischemic stroke (AIS) and cancer are at exceptionally high risk for recurrent thromboembolism (RTE), which includes venous thromboembolism (VTE) and arterial thromboembolism (ATE). Yet contemporary data from Chinese patients remain scarce.
methodsIn this retrospective, observational study conducted at Tianjin First Central Hospital (June 2023-December 2024), consecutive adults with AIS and cancer were enrolled. The primary outcomes during 6 months follow-up were recurrent VTE།composite VTE (symptomatic and incidental VTE requiring treatment), recurrent stroke [cerebral infarction, transient ischemic attack (TIA), and systemic embolism (SE)], and bleeding (major bleeding and clinically significant non-major bleeding). Multivariable logistic regression was used to identify independent predictors of each endpoint.
resultsAmong 218 eligible patients, 49 (22.5%) had baseline VTE, of whom 45 (91.8%) were asymptomatic. Baseline VTE was independently predicted by cryptogenic stroke subtype (OR 2.70; 95% CI 1.101-6.621; P = 0.030) and D-dimer > 1.2 µg/mL (OR 3.619; 95% CI 1.505-8.703; P = 0.004). During follow-up, 25 patients (11.5%) experienced composite VTE, 71 patients (32.6%) experienced recurrent stroke, and 21 patients (9.6%) experienced bleeding. Multivariable analysis revealed that D-dimer > 1.2 µg/mL independently predicted recurrent VTE (OR 3.501; 95% CI 1.012-12.112; P = 0.048), whereas cancer metastasis portended recurrent stroke (OR 3.155; 95% CI 1.423-6.995; P = 0.005), and anticoagulant therapy was associated with an increased bleeding risk (OR 9.458; 95% CI 1.158-77.267; P = 0.036).
conclusionsIn this Chinese cohort of patients with acute ischemic stroke (AIS) and cancer, routine screening revealed venous thromboembolism (VTE) in roughly one-fifth of participants at baseline, most of whom were asymptomatic. Exploratory multivariable analyses indicated that cryptogenic stroke subtype and D-dimer > 1.2 µg/mL were associated with prevalent VTE, while D-dimer > 1.2 µg/mL also predicted recurrent VTE. These findings suggested that D-dimer guided VTE screening might be considered at the time of stroke presentation, even in the absence of symptoms. Cancer metastasis showed an association with recurrent stroke, whereas anticoagulant therapy was linked to a higher bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.